Drugs / SOBI002
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Clinical hold | Other | — | — | 2014-10-30 | “Placed the phase 1 study of SOBI002 on clinical hold” sobi.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02083666 | Dec 2013 → Nov 2014 | — | Swedish Orphan Biovitrum | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOBI002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02083666 ↗ |
| Route | Intravenous | “SOBI002 will either be administered subcutaneously or intravenously.” NCT02083666 ↗ |
| Route | Subcutaneous | “SOBI002 will either be administered subcutaneously or intravenously.” NCT02083666 ↗ |